Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non‐small cell lung cancer

Autor: Siqi Liu, Tingting Liang, Xuan Zhang, Quanhang Jiang
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
non‐small cell lung cancer
Adult
Male
Lung Neoplasms
Adolescent
MUC1
Enzyme-Linked Immunosorbent Assay
General Biochemistry
Genetics and Molecular Biology
03 medical and health sciences
Young Adult
0302 clinical medicine
Antigen
Carcinoma
Non-Small-Cell Lung
Medicine
natural antibody
Humans
IL-2 receptor
Lung cancer
CD25
lcsh:QH301-705.5
neoplasms
Research Articles
Early Detection of Cancer
Aged
Vascular Endothelial Growth Factor Receptor-1
biology
business.industry
Mucin
Mucin-1
Interleukin-2 Receptor alpha Subunit
Middle Aged
medicine.disease
030104 developmental biology
lcsh:Biology (General)
VEGFR1
030220 oncology & carcinogenesis
Immunoglobulin G
Cancer research
biology.protein
Biomarker (medicine)
Tumor necrosis factor alpha
Female
Antibody
business
Research Article
Zdroj: FEBS Open Bio
FEBS Open Bio, Vol 10, Iss 7, Pp 1288-1294 (2020)
ISSN: 2211-5463
Popis: We previously demonstrated that a deficiency of natural antibodies against CD25, Mucin 1 (MUC1), and vascular endothelial growth factor receptor 1 (VEGFR1) could contribute to high risk of non‐small cell lung cancer (NSCLC). This study was designed to investigate whether natural IgG antibodies against POU domain class 5 transcription factor 1 (POU5F1), tumor necrosis factor‐α (TNF‐α), and the combination of CD25, VEGFR1, and MUC1 could play an anti‐tumorigenic role against developing NSCLC. An ELISA was developed in‐house to examine plasma IgG against peptide antigens derived from POU5F1, TNF‐α, and a combination of peptide antigens derived from CD25, MUC1, and VEGFR1 in 211 patients with NSCLC and 200 healthy controls. Mann–Whitney U test demonstrated that plasma IgG levels for the combination of peptide antigens derived from CD25, MUC1, and VEGFR1 were significantly lower in NSCLC patients than control subjects (Z = −12.978, P
Group I as an early stage (stages 1 and 2A, n = 121), group II as stage 2B (n = 41), and group III as stages 3 and 4 (n = 49). ROC curve analysis showed that the CD25‐MUC1‐VEGFR1 combination‐based ELISA showed the largest AUC of 0.883 (95% CI 0.844–0.923) with a sensitivity of 49.6% against the specificity of 95.0% in patients with early‐stage NSCLC. Natural antibodies against the combination of CD25, VEGFR1, and MUC1 may be an effective biomarker for early diagnosis of NSCLC.
Databáze: OpenAIRE
Externí odkaz: